Christine Joerres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christine Joerres has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Alastair Noyce
1 shared publicationAmy Keller
1 shared publicationAnish Bhattacharyya
Affiliation Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
1 shared publicationBarbara Onen
1 shared publication- Christopher G. Knight
University of Manchester
1 shared publication - Danna R. Gifford
The University of Manchester
1 shared publication
Latest Publications
- Open Access
- 23 July 2024
- Published by Elsevier in Thrombosis Update
- Vol. 16
Assessing the prevalence of nitrous oxide usage in patients aged 35 years or under presenting with unprovoked VTE between 2021-2023
- 23 July 2024
- Published by Elsevier in Thrombosis Update
- Vol. 16
Open AccessAssessing the prevalence of nitrous oxide usage in patients aged 35 years or under presenting with unprovoked VTE between 2021-2023
- Open Access
- 13 June 2023
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 19 (6) , e1010791
Mutators can drive the evolution of multi-resistance to antibiotics
Antibiotic combination therapies are an approach used to counter the evolution of resistance; their purported benefit is they can stop the successive emergence of independent resistance mutations in the same genome. Here, we show that bacterial populations with ‘mutators’, organisms with defects in DNA repair, readily evolve resistance to combination antibiotic treatment when there is a delay in reaching inhibitory concentrations of antibiotic—under conditions where purely wild-type populations cannot. In populations of Escherichia coli subjected to combination treatment, we detected a diverse array of acquired mutations, including multiple alleles in the canonical targets of resistance for the two drugs, as well as mutations in multi-drug efflux pumps and genes involved in DNA replication and repair. Unexpectedly, mutators not only allowed multi-resistance to evolve under combination treatment where it was favoured, but also under single-drug treatments. Using simulations, we show that the increase in mutation rate of the two canonical resistance targets is sufficient to permit multi-resistance evolution in both single-drug and combination treatments. Under both conditions, the mutator allele swept to fixation through hitch-hiking with single-drug resistance, enabling subsequent resistance mutations to emerge. Ultimately, our results suggest that mutators may hinder the utility of combination therapy when mutators are present. Additionally, by raising the rates of genetic mutation, selection for multi-resistance may have the unwanted side-effect of increasing the potential to evolve resistance to future antibiotic treatments.
- 13 June 2023
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 19 (6) , e1010791
Open AccessMutators can drive the evolution of multi-resistance to antibiotics
Antibiotic combination therapies are an approach used to counter the evolution of resistance; their purported benefit is they can stop the successive emergence of independent resistance mutations in the same genome. Here, we show that bacterial populations with ‘mutators’, organisms with defects in DNA repair, readily evolve resistance to combination antibiotic treatment when there is a delay in reaching inhibitory concentrations of antibiotic—under conditions where purely wild-type populations cannot. In populations of Escherichia coli subjected to combination treatment, we detected a diverse array of acquired mutations, including multiple alleles in the canonical targets of resistance for the two drugs, as well as mutations in multi-drug efflux pumps and genes involved in DNA replication and repair. Unexpectedly, mutators not only allowed multi-resistance to evolve under combination treatment where it was favoured, but also under single-drug treatments. Using simulations, we show that the increase in mutation rate of the two canonical resistance targets is sufficient to permit multi-resistance evolution in both single-drug and combination treatments. Under both conditions, the mutator allele swept to fixation through hitch-hiking with single-drug resistance, enabling subsequent resistance mutations to emerge. Ultimately, our results suggest that mutators may hinder the utility of combination therapy when mutators are present. Additionally, by raising the rates of genetic mutation, selection for multi-resistance may have the unwanted side-effect of increasing the potential to evolve resistance to future antibiotic treatments.